Back
Sep 29
Education

EDU 20 - ASTRO Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma Guideline: A Case-Based Interactive Discussion

10:45am - 12:00pm PT

MODERATOR(S)

Debra Yeboa, MD - MD Anderson Cancer Center

Joseph Bovi, MD - Medical College of Wisconsin

session DESCRIPTION

World Health Organization (WHO) grade 4 adult-type diffuse glioma remains one of the most challenging malignancies to treat, demanding a multidisciplinary and evidence-based approach. The role of radiation therapy (RT) has evolved since the publication of the 2016 ASTRO Guideline on Radiation Therapy for Glioblastoma with this guideline serving as a replacement. This session will provide an in-depth overview of the updated guidance, highlighting key changes in molecular diagnostics, RT protocols and systemic therapies. Attendees will gain practical insight for implementing the guideline, with case-based discussions demonstrating how to tailor treatment strategies to individual patients. Emphasis will also be placed on optimizing care pathways and fostering collaboration among neurosurgeons, neuro-oncologists, radiation oncologists and supportive care teams to enhance outcomes. This session is essential for clinicians seeking to stay at the forefront of WHO grade 4 diffuse glioma management and ensure their patients benefit from the latest evidence-based strategies. Whether you are a seasoned specialist or new to neuro-oncology, this education session will equip you with actionable knowledge to improve patient care in this rapidly evolving field.

learning objectives

  1. Discuss indications and appropriate techniques for reirradiation in patients with grade 4 diffuse gliomas whose disease recurs following completion of standard first-line therapy.
  2. Identify indications for postoperative RT and postoperative chemoradiation and discuss the evidence for appropriate dose-fractionation regimens for external beam radiation therapy (EBRT) after biopsy/resection in patients with WHO grade 4 adult-type diffuse gliomas and how might treatment vary based on pretreatment characteristics.
  3. Discuss appropriate target volumes and techniques for definitive EBRT.

Credits

AMA PRA Category 1 Credits: 1.25

Presentations